Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Author Correction: Atopic dermatitis.

Nature reviews. Disease primers·2026
Same author

Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin).

Dermatology and therapy·2026
Same author

A Durability Index for Atopic Dermatitis: Indirect Comparison of Lebrikizumab, Dupilumab, and Tralokinumab in Maintaining Efficacy Under Variable Treatment Adherence.

Dermatology and therapy·2026
Same author

Atopic dermatitis.

Nature reviews. Disease primers·2026
Same author

Future directions in atopic dermatitis.

Journal of the American Academy of Dermatology·2026
Same author

Loss-of-function variants in EPHX3 cause nonsyndromic epidermal differentiation disorders.

The British journal of dermatology·2026
Same journal

Primary aldosteronism.

Nature reviews. Disease primers·2026
Same journal

Primary aldosteronism.

Nature reviews. Disease primers·2026
Same journal

Buruli ulcer in Africa: between innovation and pragmatism.

Nature reviews. Disease primers·2026
Same journal

Integrating sexual health into care for patients with cancer and chronic illness.

Nature reviews. Disease primers·2026
Same journal

Chronic graft-versus-host disease.

Nature reviews. Disease primers·2026
See all related articles

Related Experiment Video

Updated: Feb 8, 2026

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment
06:47

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment

Published on: September 27, 2017

10.2K

Atopic dermatitis.

Stephan Weidinger1, Lisa A Beck2, Thomas Bieber3,4

  • 1Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Kiel, Germany. sweidinger@dermatology.uni-kiel.de.

Nature Reviews. Disease Primers
|June 23, 2018
PubMed
Summary
This summary is machine-generated.

Atopic dermatitis (AD) is a common inflammatory skin disease causing itch and lesions. Research explores its causes, including barrier dysfunction and immune responses, to develop targeted therapies.

More Related Videos

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
10:27

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

25.0K
Contact Hypersensitivity as a Murine Model of Allergic Contact Dermatitis
08:25

Contact Hypersensitivity as a Murine Model of Allergic Contact Dermatitis

Published on: September 26, 2022

3.5K

Related Experiment Videos

Last Updated: Feb 8, 2026

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment
06:47

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment

Published on: September 27, 2017

10.2K
Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
10:27

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

25.0K
Contact Hypersensitivity as a Murine Model of Allergic Contact Dermatitis
08:25

Contact Hypersensitivity as a Murine Model of Allergic Contact Dermatitis

Published on: September 26, 2022

3.5K

Area of Science:

  • Dermatology
  • Immunology
  • Genetics

Background:

  • Atopic dermatitis (AD) is a prevalent chronic inflammatory skin condition affecting up to 20% of the population, significantly impacting quality of life.
  • AD presents with intense pruritus, eczematous lesions, and a variable clinical course, often co-occurring with asthma and allergic rhinitis.
  • Genetic factors, such as filaggrin deficiency, contribute to impaired epidermal barrier function, promoting inflammation and immune cell infiltration.

Purpose of the Study:

  • To provide a comprehensive overview of the pathophysiology of atopic dermatitis.
  • To discuss the various contributing factors to AD onset and clinical manifestations.
  • To review current and emerging therapeutic strategies for managing atopic dermatitis.

Main Methods:

  • Review of existing literature on atopic dermatitis.
  • Analysis of pathophysiological mechanisms including epidermal barrier, immune response, and microbiota.
  • Summary of current treatment modalities and advancements in targeted therapies.

Main Results:

  • Key mechanisms include epidermal barrier defects, T helper 2-skewed immune responses, skin microbiota dysbiosis, and neuroinflammation.
  • Filaggrin deficiency is linked to barrier impairment, facilitating inflammation and T cell infiltration.
  • Current treatments range from topical agents and phototherapy to systemic immunosuppressants, with new targeted therapies under development.

Conclusions:

  • Atopic dermatitis is a complex disease with multifactorial etiology involving genetic, immune, and environmental factors.
  • Understanding these mechanisms is crucial for developing effective treatments.
  • Targeted small molecules and biologic therapies show promise for moderate-to-severe atopic dermatitis.